Panel Ecosystem Innovation track
Most Favoured Nations: A Game-Changer for Biotech Dealmaker?
Wed, Nov 11, 2026 · 10:00–10:45 AM CET Ecosystem Innovation Stage, Koelnmesse
About this session
The introduction of the Most Favoured Nation (MFN) drug pricing policy has upended traditional biopharma dealmaking, forcing companies to rethink strategies for maintaining premium pricing in the U.S. market. What exactly do these plans entail? How far advanced are these plans, and which segments of the U.S. market are affected? What does the MFN policy mean for Europe? And what must companies consider in the future when launching innovative drugs on the global market? Industry leaders will discuss the impact on launching drugs in Europe, the challenges of pricing ex-U.S.
Speakers
-
VP, Market Access Germany, Member of the Executive Board · Bristol-Myers Squibb
Panelist
-
Head of Public & Government Affairs Germany · Boehringer Ingelheim Corporate Center
Panelist
